Single Ascending Dose Study of PRX003 in Healthy Subjects

March 14, 2016 updated by: Prothena Biosciences Limited

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX003 Administered by Intravenous Infusion in Healthy Subjects

This single ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX003 in approximately 40 healthy subjects.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Texas
      • San Antonio, Texas, United States
        • Worldwide Clinical Trials Early Phase Services

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 50 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Healthy subjects
  • Body mass index (BMI) between 18-32 kg/m2 with a minimum weight of 45 kg
  • Female subjects must be surgically sterile or post-menopausal or if of child-bearing potential must use contraception
  • Male subjects and their partners of childbearing potential must use contraception

Exclusion Criteria:

  • Positive test for drug of abuse
  • Past or current history of alcohol abuse
  • Positive for TB, hepatitis B, hepatitis C or HIV infection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Other: Placebo
Experimental: PRX003
Drug: PRX003

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety and tolerability as determined by number of subjects with adverse events
Time Frame: Up to 3 months
Up to 3 months
Determination of pharmacokinetics parameters-(Cmax)
Time Frame: Up to 3 months
maximum concentration (Cmax)
Up to 3 months
Determination of pharmacokinetics parameters-(AUClast)
Time Frame: Up to 3 months
area under the concentration-time curve from time zero to the last quantifiable concentration time-point (AUClast)
Up to 3 months
Determination of pharmacokinetics parameters-(AUCinf)
Time Frame: Up to 3 months
area under the concentration-time curve from time zero extrapolated to infinity (AUCinf)
Up to 3 months
Determination of pharmacokinetics parameters-elimination rate constant
Time Frame: Up to 3 months
elimination rate constant
Up to 3 months
Determination of pharmacokinetics parameters-(t½)
Time Frame: Up to 3 months
terminal elimination half life (t½)
Up to 3 months
Determination of pharmacokinetics parameters-(CL)
Time Frame: Up to 3 months
clearance (CL)
Up to 3 months
Determination of pharmacokinetics parameters-(Vd)
Time Frame: Up to 3 months
apparent volume of distribution (Vd)
Up to 3 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Immunogenicity as determined by measurement of anti-PRX003 antibodies
Time Frame: Up to 3 months
Up to 3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Prothena Biosciences Limited

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2015

Primary Completion (Actual)

February 1, 2016

Study Completion (Actual)

February 1, 2016

Study Registration Dates

First Submitted

May 28, 2015

First Submitted That Met QC Criteria

May 29, 2015

First Posted (Estimate)

June 1, 2015

Study Record Updates

Last Update Posted (Estimate)

March 16, 2016

Last Update Submitted That Met QC Criteria

March 14, 2016

Last Verified

March 1, 2016

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PRX003-CL001

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Psoriasis

Clinical Trials on Placebo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe